Recent Updates — COPL

Copley Acquisition Corp and Ignite Proteomics mutually terminated their previously announced business combination agreement effective October 9, 2026. The termination releases all parties from further rights or obligations under the original deal, with each side bearing its own expenses. Copley intends to continue pursuing an alternative business combination before its November 2, 2026 deadline. Copley Acquisition Corp operates as a blank check company focused on identifying and merging with private businesses.

On October 6, 2026, Copley Acquisition Corp amended and restated its convertible promissory note with Copley Acquisition Sponsors LLC, increasing the maximum aggregate principal amount from $450,000 to $900,000. The note bears no interest and matures on the earlier of a business combination or liquidation. Sponsor may convert outstanding amounts into units at $7.00 per unit. Proceeds are for working capital.

Copley Acquisition Corp entered into a Business Combination Agreement with Ignite Proteomics, LLC and Ignite Proteomics Holdings, Inc. to consummate a merger that will result in Ignite Proteomics becoming a publicly traded company. The aggregate consideration for the merger is $150,000,000, to be paid in newly issued shares of Pubco Common Stock at a valuation of $10.00 per share. Copley Acquisition Corp is a special purpose acquisition company (SPAC) that seeks to complete a business combination with a target company.